Cardiff OncologyCRDF
CRDF
About: Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Employees: 32
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
439% more call options, than puts
Call options by funds: $2.19M | Put options by funds: $406K
13% more capital invested
Capital invested by funds: $29.7M [Q2] → $33.4M (+$3.72M) [Q3]
9% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 23
3.03% less ownership
Funds ownership: 29.9% [Q2] → 26.87% (-3.03%) [Q3]
8% less funds holding
Funds holding: 89 [Q2] → 82 (-7) [Q3]
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
135%
upside
Avg. target
$11.50
170%
upside
High target
$13
205%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler Joseph Catanzaro 32% 1-year accuracy 10 / 31 met price target | 135%upside $10 | Overweight Maintained | 13 Dec 2024 |
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 121 / 308 met price target | 205%upside $13 | Buy Maintained | 8 Nov 2024 |
Financial journalist opinion
Based on 6 articles about CRDF published over the past 30 days
Positive
Seeking Alpha
1 week ago
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +
The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational improvements, Ready Capital Corporation faces liquidity risks, and TORM plc is crucial despite energy sector volatility. Esperion Therapeutics' breakout and Cardiff Oncology's promising trial data present compelling buy opportunities, while Advantest Corporation's high valuation suggests caution.
Positive
Seeking Alpha
1 week ago
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when combined with standard chemotherapy and bevacizumab, but patient numbers remain low, necessitating further validation. Financially, CRDF's equity raise extends their cash runway, supporting the continued development and reducing immediate financial risk.
Positive
Zacks Investment Research
1 week ago
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.
Positive
Seeking Alpha
1 week ago
Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer
Cardiff Oncology's Phase 2 trial data for Onvansertib in metastatic colorectal cancer shows dose-related outperformance of standard care, with a combined ORR of 57% versus 33% in the control arm. The company plans to discuss with the FDA to potentially make the CRDF-004 trial a registrational trial, aiming for accelerated approval based on ORR. Cardiff's recent $40 million oversubscribed direct offering strengthens its financial position, ensuring over two years of operational funding.
Neutral
GlobeNewsWire
1 week ago
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the pricing of an underwritten offering of 15,384,619 shares of its common stock at an offering price of $2.60 per share, before deducting underwriting discounts and commissions. All of the shares of common stock are being offered by the Company. The financing included participation from new mutual fund and healthcare dedicated investors, along with support from existing investors.
Neutral
GlobeNewsWire
1 week ago
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm -
Negative
Zacks Investment Research
1 month ago
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC -
Positive
Seeking Alpha
2 months ago
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales. Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors, particularly in bevacizumab-naïve patients, with impressive objective response rates and progression-free survival. Positive data from the ongoing CRDF-004 trial could lead to significant upside for Cardiff, attracting potential partnerships or acquisition interest from big pharma, including Pfizer.
Neutral
Seeking Alpha
4 months ago
Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point
Cardiff Oncology, Inc. results from the phase 2 CRDF-004 study, using onvansertib + Folfiri + bevacizumab for the treatment of patients with RAS-mutant mCRC, expected in the 2nd half of 2024. The global colorectal cancer market is expected to reach $30.09 billion by 2033; It said that about 50% of mCRC patients harbor the RAS mutation. A new phase 2 investigator-sponsored study, using onvansertib + Nalirifox for the treatment of 1st-line PDAC patients, will be deployed soon.
Charts implemented using Lightweight Charts™